This section highlights FDA-related milestones and regulatory updates for drugs developed by RenovoRx (RNXT).
Over the past two years, RenovoRx has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as
TIGeR-PaC, RenovoCath, and TAMP. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.
Select a button below to view the list of FDA events for that drug.
TIGeR-PaC FDA Regulatory Timeline and Events
TIGeR-PaC is a drug developed by RenovoRx for the following indication: To provide targeted intra-arterial delivery of FDA-approved chemotherapy, gemcitabine, to treat locally advanced pancreatic cancer (LAPC) following stereotactic body radiation therapy (SBRT).
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- TIGeR-PaC
- Announced Date:
- August 25, 2026
- Indication:
- To provide targeted intra-arterial delivery of FDA-approved chemotherapy, gemcitabine, to treat locally advanced pancreatic cancer (LAPC) following stereotactic body radiation therapy (SBRT).
Announcement
RenovoRx, Inc. announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the journal Cancer Chemotherapy and Pharmacology.
Read Announcement- Drug:
- TIGeR-PaC
- Announced Date:
- April 23, 2026
- Indication:
- To provide targeted intra-arterial delivery of FDA-approved chemotherapy, gemcitabine, to treat locally advanced pancreatic cancer (LAPC) following stereotactic body radiation therapy (SBRT).
Announcement
RenovoRx, Inc. announce that an abstract submission from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
AI Summary
RenovoRx announced that an abstract from a pharmacokinetic (PK) and pharmacodynamic (PD) sub‑study of its ongoing Phase III TIGeR‑PaC trial in locally advanced pancreatic cancer has been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The ASCO meeting runs May 29–June 2, 2026, in Chicago, and the abstract will be published online on May 21, 2026 at 5:00 P.M. ET as publication number E16463. The abstract is titled “The TIGeR‑PaC Phase III Clinical Trial Examining Intra‑Arterial Gemcitabine Versus Intravenous Gemcitabine: Pharmacokinetic and Pharmacodynamic Sub‑Study.”
The company noted that the intra‑arterial gemcitabine (IAG) combination, enabled by the RenovoCath device, remains investigational and is not approved for commercial sale. RenovoRx included a standard forward‑looking statement saying it does not undertake an obligation to update such statements except as required by law.
Read Announcement- Drug:
- TIGeR-PaC
- Announced Date:
- March 26, 2026
- Indication:
- To provide targeted intra-arterial delivery of FDA-approved chemotherapy, gemcitabine, to treat locally advanced pancreatic cancer (LAPC) following stereotactic body radiation therapy (SBRT).
Announcement
RenovoRx, Inc. announced the Company has achieved a key milestone in its ongoing Phase III TIGeR‑PaC clinical trial by surpassing 100 randomized patients and remains on track for enrollment completion in the first half of 2026, with final data expected in 2027.
AI Summary
RenovoRx announced a key milestone in its Phase III TIGeR‑PaC trial, reporting it has surpassed 100 randomized patients and remains on track to finish enrollment in the first half of 2026. As of March 24, 2026, the study had randomized 104 patients and recorded 72 events (deaths). The trial’s protocol requires 114 randomized patients and 86 events to complete the final analysis, and the company expects to meet the enrollment target by the end of H1 2026.
The trial has completed two pre‑planned interim analyses, triggered at the 26th event (2023) and the 52nd event (2025); in both reviews the independent data monitoring committee recommended continuing the study. RenovoRx anticipates final data from the TIGeR‑PaC trial in 2027, keeping the program on its stated timeline toward a conclusive analysis.
Read Announcement- Drug:
- TIGeR-PaC
- Announced Date:
- April 29, 2025
- Indication:
- To provide targeted intra-arterial delivery of FDA-approved chemotherapy, gemcitabine, to treat locally advanced pancreatic cancer (LAPC) following stereotactic body radiation therapy (SBRT).
Announcement
RenovoRx, Inc announced that Johns Hopkins Medicine is now initiated to enroll patients with locally advanced pancreatic cancer (LAPC) in RenovoRx's ongoing Phase III TIGeR-PaC clinical trial.
AI Summary
RenovoRx, Inc. announced that Johns Hopkins Medicine will now enroll patients with locally advanced pancreatic cancer (LAPC) in its ongoing Phase III TIGeR-PaC clinical trial. The enrollment will take place at the Sibley Memorial Hospital campus, adding to a network of leading U.S. cancer centers participating in the trial. This study evaluates the intra-arterial delivery of gemcitabine using RenovoRx’s FDA-cleared RenovoCath device and its Trans-Arterial Micro-Perfusion (TAMP™) technology. Johns Hopkins Medicine’s involvement will help drive patient recruitment, with full enrollment expected to be reached by 2025. Dr. Valerie Lee, a medical oncologist with expertise in gastrointestinal cancers, has been appointed as the local Principal Investigator for the trial. Her role supports the effort to advance new, targeted treatment methods for pancreatic cancer, offering hope for improved outcomes in this challenging patient population.
Read Announcement- Drug:
- TIGeR-PaC
- Announced Date:
- December 11, 2024
- Indication:
- To provide targeted intra-arterial delivery of FDA-approved chemotherapy, gemcitabine, to treat locally advanced pancreatic cancer (LAPC) following stereotactic body radiation therapy (SBRT).
Announcement
RenovoRx, Inc. announced today that SCRI Oncology Partners in Nashville, TN, is now enrolling patients with locally advanced pancreatic cancer (LAPC) in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial. SCRI Oncology Partners joins esteemed clinical sites throughout United States participating in the study.
AI Summary
RenovoRx, Inc. announced that SCRI Oncology Partners in Nashville, TN, is now enrolling patients with locally advanced pancreatic cancer (LAPC) in its pivotal Phase III TIGeR-PaC clinical trial. The study is evaluating the TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, a novel approach that delivers gemcitabine directly to tumors via the FDA-cleared RenovoCath device. This targeted intra-arterial infusion aims to improve overall survival and reduce the systemic side effects often seen with standard intravenous chemotherapy. SCRI Oncology Partners joins other respected U.S. clinical sites in this trial, supporting RenovoRx's goal of accelerating patient enrollment. The collaboration is expected to help the study reach enrollment completion in the first half of 2025, potentially offering new hope in the treatment of LAPC.
Read Announcement
RenovoCath FDA Regulatory Timeline and Events
RenovoCath is a drug developed by RenovoRx for the following indication: Solid Tumors.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- RenovoCath
- Announced Date:
- August 25, 2026
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced the publication of pharmacokinetic and pharmacodynamic (PK/PD) data from a sub-study of its ongoing Phase III TIGeR-PaC clinical trial (NCT03257033) in the journal Cancer Chemotherapy and Pharmacology.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- August 11, 2026
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announce completion of enrollment in the Company’s Phase III TIGeR-PaC trial in locally advanced pancreatic cancer (LAPC).
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- June 11, 2026
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced the publication of a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports.
AI Summary
RenovoRx, Inc. said a peer-reviewed case study from researchers at Moffitt Cancer Center was recently published in Radiology Case Reports. The report looked at a patient treated with the company’s RenovoCath-enabled TAMP method, which delivered gemcitabine directly to the tumor area.
According to Dr. Kis, the patient completed all eight treatments without complications. At the four-month follow-up, PET-CT scans showed the disease was stable, and metabolic imaging showed signs of response, including a 52% drop in FDG activity at the treatment site. The company said the results support further study of the approach, but the product candidate is still under investigation and has not been approved for sale.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- February 4, 2026
- Target Action Date:
- February 6, 2026
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced that new clinical data will be presented at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026.
AI Summary
RenovoRx, Inc. announced it will present new clinical data at the 2026 Society of Interventional Oncology (SIO) Annual Scientific Meeting on February 6, 2026. The data focus on real‑time intra‑arterial pressure monitoring during TAMP procedures and show how pressure measurements reveal the mechanics of targeted drug delivery near tumors. These measurements may help clinicians understand and adjust the factors that influence effective intra‑arterial chemotherapy delivery.
Dr. Laing noted that real‑time pressure readings give valuable insight and can help refine delivery techniques. Ramtin Agah, RenovoRx’s chairman and CMO, said the findings support routine intra‑arterial monitoring to improve standardization, optimize delivery conditions, and potentially enhance clinical outcomes with the TAMP therapy platform.
The study is co‑authored by teams from leading centers, including Sutter Health and Atrium Health at Wake Forest University School of Medicine. RenovoRx will present the full clinical results at the SIO meeting on February 6, 2026.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- January 8, 2026
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced that a new clinical data abstract from a pharmacokinetic (PK) and pharmacodynamic sub‑study of its ongoing Phase III TIGeR‑PaC clinical trial will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2026 ("ASCO GI"), being held today through January 10th in San Francisco, California.
AI Summary
RenovoRx announced a clinical data abstract from a pharmacokinetic (PK) and pharmacodynamic (PD) sub‑study of its Phase III TIGeR‑PaC trial will be presented at the ASCO GI Symposium (Jan 8–10, 2026) in San Francisco. The abstract, led by Dr. Paula M. Novelli of UPMC, is titled "Intra-arterial Gemcitabine Versus Intravenous Gemcitabine" and compares intra‑arterial gemcitabine delivered with the TAMP platform (IAG) to standard IV administration.
The sub‑study reviewed 16 patients at six sites (11 IAG, 5 IV). IAG showed lower systemic gemcitabine and higher levels of an inactive metabolite versus IV. Increased metabolite levels correlated with drops in CA 19‑9, a biomarker of chemotherapy response. By limiting systemic exposure and converting drug locally, IAG via TAMP may increase tumor drug effect while reducing common chemotherapy side effects. These PK/PD results support continued study of TAMP and IAG for locally advanced pancreatic cancer.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- August 6, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced strong progress in its commercialization efforts, including its growing customer base and the hiring of experienced medical device sales leader Philip Stocton as Senior Director of Sales and Market Development to lead the execution of RenovoRx's commercialization efforts.
AI Summary
Since December 2024, RenovoRx has rapidly expanded its commercial footprint for RenovoCath. Thirteen leading cancer centers, including National Cancer Institute–designated academic and community hospitals, are now approved to purchase the FDA-cleared device, up from five in the first quarter of 2025.
Four of these centers have used RenovoCath in patients and all have placed repeat orders. This growing customer base highlights strong clinical demand in the US for localized solid tumor drug-delivery options beyond traditional chemotherapy methods.
To drive further growth, RenovoRx hired Philip Stocton as Senior Director of Sales and Market Development. He previously consulted on the RenovoCath launch planning. Mr. Stocton brings over 25 years of MedTech experience at Terumo, Johnson & Johnson, Varian/Siemens, and Sirtex Medical. Over the past decade, he has specialized in interventional oncology and will coordinate and expand RenovoRx’s commercialization strategy across domestic and international markets.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- July 28, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced the launch of the PanTheR Post-Marketing Registry Study (NCT06805461).
AI Summary
RenovoRx, Inc. launched the PanTheR Post-Marketing Registry Study (NCT06805461) to expand safety and performance data on its FDA-cleared RenovoCath device. This multi-center, observational study will track long-term safety and survival outcomes in patients with solid tumors. By capturing real-world data across diverse cancer types, PanTheR aims to reveal device effectiveness and guide future trials.
Patient enrollment begins before September 2025, with each center purchasing RenovoCath devices from RenovoRx. The University of Vermont Cancer Center is the first site to start enrollment, led by surgical oncologist Dr. Conor O’Neill. More centers are expected to join soon.
PanTheR’s real-world registry is designed to demonstrate RenovoCath’s long-term safety profile and potential to improve patient outcomes. RenovoRx expects this data to support evidence-based treatment strategies and fuel innovation in targeted drug delivery for solid tumor care.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- May 6, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc announced that it has received an Issue Notification from the U.S. Patent and Trademark Office (USPTO) indicating that U.S. patent NO. 12,290,564, becomes effective today, May 6, 2025.
AI Summary
RenovoRx, Inc. announced a significant milestone for its oncology innovations today. The company received an Issue Notification from the U.S. Patent and Trademark Office, confirming that U.S. patent No. 12,290,564, titled “Methods for Treating Tumors,” becomes effective on May 6, 2025. This patent expands the protection for RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform by safeguarding methods for locally delivering drugs near tumors with its proprietary RenovoCath device. The protection provided by the patent extends until November 2037, further strengthening RenovoRx’s intellectual property portfolio. This development supports the company's efforts to advance and scale the commercialization of the RenovoCath device, positioning it as a key player in targeted oncology treatments.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- April 16, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc announced that it is increasing production of its FDA-cleared RenovoCath catheter-based device in order to meet increased demand for the targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists.
AI Summary
RenovoRx, Inc. announced it is ramping up production of its FDA-cleared RenovoCath catheter-based device to meet rising demand from oncologists and interventional radiologists. The device is designed for the targeted delivery of diagnostic and therapeutic agents, providing doctors with a precise way to treat patients. Manufactured by Medical Murray Inc. in North Barrington, IL, RenovoCath isolates blood flow to deliver fluids to specific sites within the peripheral vascular system.
The company expects that increased production will help boost revenue, with early projections indicating low six-figure earnings in the first quarter of 2025 and ongoing growth thereafter. RenovoRx’s move reflects its commitment to addressing market needs and capturing a share of an estimated $400 million peak annual U.S. sales opportunity, while continuing to support innovative, targeted oncology therapies made in America.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- April 1, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. provided business updates
AI Summary
RenovoRx, Inc. announced key business updates for Q4 2024 and the full year, highlighting initial revenue generation from its FDA-cleared RenovoCath device. The company reported approximately $43,000 in standalone sales during Q4 and expects revenues to grow sequentially in 2025, driven by new customer purchase orders and repeat orders from early adopters. RenovoRx stressed that its current commercial strategy can be executed without significantly increasing capital expenditures, regardless of whether it self-commercializes or partners with a larger organization. Additionally, the company noted a robust cash position of $7.2 million as of December 31, 2024, bolstered by an additional $12.1 million gross proceeds from a recent public offering. These funds will support ongoing expansion initiatives, including scaling RenovoCath sales and advancing the Phase III TIGeR-PaC clinical trial toward key milestones.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- March 28, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc announced today that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting on March 27 – 29, 2025 in Tampa, FL: ePoster P379.
AI Summary
RenovoRx, Inc. announced that a new human pharmacokinetic (PK) data abstract was presented at the Society of Surgical Oncology (SSO) 2025 Annual Meeting in Tampa, FL, held from March 27–29, 2025. The abstract, showcased as ePoster P379, focused on the company’s Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is engineered for targeted chemotherapy delivery.
The data presented at the meeting demonstrated that localized, intra-arterial delivery of gemcitabine using the FDA-cleared RenovoCath® device resulted in lower systemic drug levels compared to standard intravenous delivery. This finding indicates that the TAMP™ platform may help reduce the toxic side effects typically associated with systemic chemotherapy. The new PK data supports the potential safety and efficacy benefits of this innovative treatment option for patients with challenging tumors.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- March 19, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announce a presentation of a new pre-clinical clinical data abstract at the upcoming Society of Surgical Oncology (SSO) 2025 Annual Meeting.
AI Summary
RenovoRx, Inc. announced that they will present a new pre-clinical clinical data abstract at the Society of Surgical Oncology (SSO) 2025 Annual Meeting in Tampa, FL. The abstract, titled “Pharmacodynamics of Intra-arterial vs. Intravenous Gemcitabine in Locally Advanced Pancreatic Cancer: Results of a Phase III Randomized Clinical Trial,” details new human pharmacokinetic (PK) and pre-clinical data. This data supports RenovoRx’s innovative Trans-Arterial Micro-Perfusion (TAMP™) therapy platform, which is designed to deliver targeted therapy directly near the tumor site while aiming to reduce toxicity compared to standard intravenous treatments.
The presentation is a key part of the company's ongoing efforts to demonstrate the effectiveness and safety of their TAMP therapy. This work may contribute to their overall approach to improving treatment options for patients battling locally advanced pancreatic cancer.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- February 26, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced continuing momentum with the Company's RenovoCath commercial strategy, with new purchase orders received from several esteemed, high volume National Cancer Institute-designated centers.
AI Summary
RenovoRx, Inc. is showing strong progress in its RenovoCath commercial strategy. The company announced new purchase orders from several high volume National Cancer Institute-designated centers, highlighting the growing acceptance of its FDA-cleared drug delivery device. These orders come on top of repeat purchases from initial customers, demonstrating that RenovoCath is gaining trust and usage in key oncology centers across the country.
With this continued momentum, RenovoRx expects to begin generating initial revenues from RenovoCath sales this quarter and anticipates further growth into 2025. The company is expanding its network of medical institutions interested in the device, which addresses significant unmet medical needs. CEO Shaun Bagai is optimistic that these partnerships will not only boost revenue but also improve outcomes by enabling targeted therapeutic delivery in oncology treatment.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- February 13, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc abstract published promising pre-clinical datafrom the use of RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which aims to optimize local and targeted drug delivery in difficult-to-treat cancers.
AI Summary
RenovoRx, Inc. presented promising pre-clinical data at SIO 2025 that highlights its patented Trans-Arterial Micro-Perfusion (TAMP) therapy platform. The study, conducted on a pig model, showed that using the RenovoCath device with dual occlusion balloons could improve targeted drug delivery in tumors with poor blood supply. By adjusting the distance between the occlusion balloons, researchers successfully isolated blood vessels, reducing off-target drug delivery and ensuring better penetration into the tumor’s microvasculature. The findings were confirmed using micro-CT imaging, which tracked how a radiopaque imaging agent filled the targeted areas. These results suggest that TAMP could optimize local drug delivery for difficult-to-treat cancers, potentially enhancing the effectiveness of treatments while minimizing side effects.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- January 27, 2025
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc announced an abstract presentation highlighting promising pharmacokinetic (known as PK) datafrom the use of RenovoRx's patented Trans-Arterial Micro-Perfusion (TAMP™) therapy platform in treating locally advanced pancreatic cancer (LAPC).
AI Summary
RenovoRx, Inc. recently announced a promising abstract presentation from the TIGeR-PaC Phase III clinical trial on its Trans-Arterial Micro-Perfusion (TAMP™) therapy platform for treating locally advanced pancreatic cancer. The study, presented by Dr. Paula Novelli at the ASCO Gastrointestinal Cancers Symposium, focused on pharmacokinetic data comparing intra-arterial versus intravenous delivery of gemcitabine. The results showed that using the TAMP system to deliver gemcitabine directly into the artery near the tumor can increase the drug's local effect while reducing the overall amount of the drug entering the bloodstream. This targeted approach may lead to improved treatment effectiveness and fewer side effects compared to the standard intravenous method, suggesting that TAMP could offer a safer and more potent option for patients with this challenging form of pancreatic cancer.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- November 20, 2024
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced today that the Northwell Health Cancer Institute ("NHCI") in New Hyde Park, NY is enrolling patients with locally advanced pancreatic cancer (LAPC) in the Company's ongoing pivotal Phase III TIGeR-PaC clinical trial.
AI Summary
RenovoRx, Inc. announced that the Northwell Health Cancer Institute in New Hyde Park, NY, is now enrolling patients with locally advanced pancreatic cancer for its ongoing pivotal Phase III TIGeR-PaC clinical trial. This study is testing the company’s innovative TAMP™ (Trans-Arterial Micro-Perfusion) therapy platform, which uses its FDA-cleared RenovoCath® device to deliver chemotherapy directly at the tumor site. The targeted intra-arterial infusion is designed to improve treatment efficacy by focusing the drug where it’s needed most while potentially reducing side effects compared to traditional systemic treatments. RenovoRx aims to complete full patient enrollment by the first half of 2025. The participation of the Northwell Health Cancer Institute, a respected cancer center, underscores the importance of the trial in advancing new treatment options for pancreatic cancer patients.
Read Announcement- Drug:
- RenovoCath
- Announced Date:
- September 25, 2024
- Indication:
- Solid Tumors
Announcement
RenovoRx, Inc. announced that it is increasing the production of its FDA-cleared RenovoCath catheter-based delivery system due to increased demand for targeted delivery of diagnostic and/or therapeutic agents from oncologists and interventional radiologists.
AI Summary
RenovoRx, Inc. announced it is ramping up production of its FDA-cleared RenovoCath catheter-based delivery system due to increased demand from oncologists and interventional radiologists. The RenovoCath device is used for the targeted delivery of diagnostic and therapeutic agents. This boost in production comes as the company strengthens its partnership with Medical Murray, its main manufacturing partner, by signing a new project work order. RenovoRx will also offer Medical Murray a warrant to purchase shares if certain manufacturing goals are met. The increased production supports the company's plans to explore more commercial opportunities for RenovoCath as a stand-alone device. This strategic move aims to meet the growing clinical demand while potentially improving patient outcomes through more precise targeted therapies.
Read Announcement
TAMP FDA Regulatory Events
TAMP is a drug developed by RenovoRx for the following indication: For the treatment of locally advanced pancreatic cancer.
This drug is under review by the U.S. Food and Drug Administration (FDA).
Below is a timeline of key regulatory milestones for this therapy.
- Drug:
- TAMP
- Announced Date:
- September 19, 2024
- Indication:
- For the treatment of locally advanced pancreatic cancer
Announcement
RenovoRx, Inc. announced that Ripal Gandhi, M.D., FSIR, FSVM will present at the Symposium on Clinical Interventional Oncology ("CIO") which is being held September 20-22, 2024, at the Loews Hotel in Miami Beach, Florida. Dr. Gandhi's presentation will highlight RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for the treatment of locally advanced pancreatic cancer ("LAPC") and recent publications of clinical data.
AI Summary
RenovoRx, Inc. announced that Dr. Ripal Gandhi, a noted professor of Interventional Radiology, will present at the Symposium on Clinical Interventional Oncology (CIO). This event is scheduled for September 20-22, 2024, at the Loews Hotel in Miami Beach, Florida. Dr. Gandhi will serve as a Course Director for the Symposium and will focus on RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform.
The presentation will cover how the TAMP therapy can be used to treat locally advanced pancreatic cancer (LAPC) by targeting tumors more precisely and potentially reducing the side effects commonly seen with systemic chemotherapy. Dr. Gandhi will also discuss recent clinical data and publications, highlighting the platform's promise as a new targeted oncology option for LAPC patients.
Read Announcement
